Join
Live feed
·
PRReleasevia Quantisnow
Pfizer Inc. logo

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

ByQuantisnow·Wall Street's wire, on your screen.
PFE· Pfizer Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PFE (Pfizer Inc.) and more on Quantisnow.